Equity Overview
Price & Market Data
Price: $14.06
Daily Change: +$1.21 / 8.61%
Daily Range: $12.69 - $14.24
Market Cap: $702,142,183
Daily Volume: 604,445
Performance Metrics
1 Week: 6.20%
1 Month: 20.09%
3 Months: 46.46%
6 Months: 40.81%
1 Year: 50.43%
YTD: 76.46%
Company Details
Employees: 353
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.